Sirolimus Trial Offers Hope for Refractory Lupus, Despite Ongoing Safety Concerns

For patients with systemic lupus erythematosus (SLE), achieving sustained disease control can be exceptionally challenging. In a recent clinical trial conducted in China, researchers evaluated the use of sirolimus—an mTOR inhibitor traditionally employed to prevent organ transplant rejection—as a potential therapeutic option for SLE that remained unresponsive to standard treatments. The study results demonstrated that a daily oral dose of sirolimus significantly reduced disease activity in these refractory patients. However, while the efficacy signals are promising, important safety concerns associated with this class of drug remain unresolved, leaving clinicians cautious about widespread clinical adoption until longer-term tolerability data is available.

Source link